Dr. Leorah A. Freeman, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 17
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 51
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
TX license 45518
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ascension Seton Medical Center Austin Austin, TX
- Dell Seton Med Center at The University of Tx Austin, TX
Medical groups
- Seton Family of Doctors (792 clinicians)
- The University of Texas at Austin (153 clinicians)
- University of Texas at Austin Dell Medical School (151 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 51
- Services billed
- 73
- Patients’ average age
- 66
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 62 | 36 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Duloxetine Hcl Other prescribers in Houston, TX | 39 |
| Baclofen Other prescribers in Houston, TX | 36 |
| Dalfampridine Er (dalfampridine) | 28 |
| Tizanidine Hcl Other prescribers in Houston, TX | 27 |
| Dextroamphetamine-Amphetamine (dextroamphetamine/amphetamine) Other prescribers in Houston, TX | 20 |
| Clonazepam Other prescribers in Houston, TX | 17 |
| Gabapentin Other prescribers in Houston, TX | 16 |
| Pregabalin Other prescribers in Houston, TX | 16 |
| Trazodone Hcl Other prescribers in Houston, TX | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 70 payments worth $61,823 in total to this clinician.
| Genzyme Corporation | $31,956 |
|---|---|
| F. Hoffmann-la Roche AG | $12,885 |
| EMD Serono, Inc. | $9,925 |
| Genentech, Inc. | $3,130 |
| Tg Therapeutics, Inc. | $3,003 |
| Genentech USA, Inc. | $572 |
| Novartis Pharmaceuticals Corporation | $233 |
| Alexion Pharmaceuticals, Inc. | $120 |
| Consulting Fee | $49,010 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $7,910 |
| Food and Beverage | $3,109 |
| Travel and Lodging | $1,795 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Aug 22, 2025 | Consulting Fee | $11,203 |
| Genzyme Corporation Oct 31, 2025 | Consulting Fee | $10,544 |
| Genzyme Corporation Sep 4, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,910 |
| EMD Serono, Inc. Oct 21, 2025 | Consulting FeeCompany’s descriptionConsulting Services (Fee For Service) | $5,908 |
| F. Hoffmann-la Roche AG Jan 20, 2025 | Consulting Fee | $5,175 |
| EMD Serono, Inc. Oct 28, 2025 | Consulting Fee Mavenclad · Neurology Company’s descriptionAdvisory Board Participation (Fee For Service) | $3,475 |
| F. Hoffmann-la Roche AG May 8, 2025 | Consulting Fee | $3,105 |
| F. Hoffmann-la Roche AG Jul 14, 2025 | Consulting Fee | $2,900 |
| Tg Therapeutics, Inc. Sep 24, 2025 | Consulting Fee BRIUMVI · Immunology | $2,363 |
| F. Hoffmann-la Roche AG Sep 24, 2025 | Consulting Fee | $1,689 |
All 19 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Oct 31, 2025 | Consulting Fee | $10,544 |
| EMD Serono, Inc. Oct 28, 2025 | Consulting Fee Mavenclad · Neurology Company’s descriptionAdvisory Board Participation (Fee For Service) | $3,475 |
| EMD Serono, Inc. Oct 21, 2025 | Consulting FeeCompany’s descriptionConsulting Services (Fee For Service) | $5,908 |
| Tg Therapeutics, Inc. Sep 24, 2025 | Consulting Fee BRIUMVI · Immunology | $2,363 |
| F. Hoffmann-la Roche AG Sep 24, 2025 | Consulting Fee | $1,689 |
| F. Hoffmann-la Roche AG Sep 24, 2025 | Travel and Lodging travel to Barcelona, Spain | $15.43 |
| Genzyme Corporation Sep 4, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,910 |
| Genzyme Corporation Sep 4, 2025 | Travel and Lodging travel to San Antonio, TX · in-kind | $213 |
| Genzyme Corporation Sep 4, 2025 | Travel and Lodging travel to San Antonio, TX | $125 |
| Genzyme Corporation Aug 22, 2025 | Consulting Fee | $11,203 |
| Genzyme Corporation Aug 22, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $829 |
| Genzyme Corporation Aug 22, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $343 |
| Genzyme Corporation Aug 22, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $200 |
| Genzyme Corporation Aug 22, 2025 | Travel and Lodging travel to Chicago, IL | $70.00 |
| Genentech, Inc. Aug 11, 2025 | Consulting Fee Ocrevus · Immunology | $1,269 |
| Genentech, Inc. Jul 30, 2025 | Consulting Fee Ocrevus · Immunology | $1,380 |
| F. Hoffmann-la Roche AG Jul 14, 2025 | Consulting Fee | $2,900 |
| F. Hoffmann-la Roche AG May 8, 2025 | Consulting Fee | $3,105 |
| F. Hoffmann-la Roche AG Jan 20, 2025 | Consulting Fee | $5,175 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $32,480 in research payments for these studies, mostly to the institutions running them.
- (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study
Tg Therapeutics, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.